HRSA's revised 340B rebate pilot raises new questions about drug purchasing, cash flow, transaction verification and administrative costs. This article examines the concerns of manufacturers and hospitals, the pilot's regulatory safeguards, and the financial, legal and operational considerations facing covered entities, pharmacies and their service providers.